mRNA vaccines clear sweeping global review of safety and effectiveness
A comprehensive global review has found that mRNA vaccines aren't just highly effective at fighting infectious diseases – they are also very safe.
Hantavirus : un vaccin contre le virus des Andes est-il prêt si la situation dégénère ?
Alors que le foyer d’hantavirus à bord du MV Hondius a déjà provoqué trois décès et plusieurs contaminations confirmées au virus des Andes (Lire plus...)
AI builds world’s first personalized cancer vaccine for a dog
Paul Conyngham, a Sydney tech entrepreneur and AI specialist, used artificial intelligence (AI) to design a personalized mRNA cancer vaccine for his rescue dog, Rosie. (Lire plus...)
COVID-19 mRNA Vaccination and 4-Year All-Cause Mortality Among Adults Aged 18 to 59 Years in France
Question Are COVID-19 mRNA vaccines associated with the long-term risk of all-cause mortality? (Lire plus...)
One molecule could usher revolutionary medicines for cancer, diabetes and genetic disease — but the US is turning its back on it
The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of uncertainty, scientists worry that revolutionary treatments for cancer, immune dysfunction and genetic disease may be left on the lab bench. (Lire plus...)
‘Universal’ cancer vaccine heading to human trials could be useful for ‘all forms of cancer’
A new mRNA-based vaccine triggers a response from the innate immune system to help arm the body against cancer, a mouse study finds. It's now in early human trials. [Lire plus...]
Vaccins à ARN Messager: Moderna promet une protection contre la plupart des maladies d’ici 2030
Moderna promet des vaccins "révolutionnaires" pour tout type de maladie, du cancer aux maladies cardiovasculaires. Certains pourraient être prêts en 2030. [Lire plus...]
L’immunologiste Steve Pascolo : « L’ARN messager peut en théorie résoudre toutes les maladies »
L'immunologiste français Steve Pascolo est au cœur de l'aventure de l'ARN messager (ARNm) vaccinal depuis vingt ans. Steve Pascolo, directeur de la plateforme "ARNm thérapeutiques" à l'université de Zurich, en Suisse, a fait sa thèse à l'Institut Pasteur avant de s’exiler en Allemagne, où ont…